Cisplatin therapy for adenoid cystic carcinoma.

Abstract

Adenoid cystic carcinoma of salivary gland origin is a relentless disease that produces a high rate of local recurrence, metastases, and death, regardless of the type of treatment. There have been few previous reports of effective chemotherapy. Cisplatin has been chosen for a trial in the treatment of patients with persistent, recurrent, or metastatic adenoid cystic carcinoma because of its demonstrated activity against a variety of tumor types, especially those with a low growth fraction. Ten patients have been included in a pilot study. Seventy percent of these patients have had a favorable subjective response and objective tumor regression. Further clinical trials are suggested.

• Authors: V L Schramm Jr, C Srodes, E N Myers
• Journal: Archives of otolaryngology (Chicago, Ill. : 1960) (Arch Otolaryngol) Vol. 107 Issue 12 Pg. 739-41 (Dec 1981) ISSN: 0003-9977 [Print] United States
• PMID: 6274284 (Publication Type: Clinical Trial, Journal Article)

Chemical References

• Cisplatin

Topics

• Carcinoma, Adenoid Cystic (drug therapy)
• Cisplatin (adverse effects, therapeutic use)
• Clinical Trials as Topic
• Humans
• Neoplasm Recurrence, Local
• Salivary Gland Neoplasms (drug therapy)